Diagnostic Radiopharmaceuticals & Contrast Media Market 2019 | Remarkable Growth Factors with Industry Size & Share, New Innovations of…

The Diagnostic Radiopharmaceuticals & Contrast Media Market research report 2019 has been estimated considering the application and regional segments, market share, and size, while the forecast for each product type and application segment has been provided for the global and regional markets. Diagnostic Radiopharmaceuticals & Contrast Media report offers detailed profiles of the key players to bring out a clear view of the competitive landscape of the Diagnostic Radiopharmaceuticals & Contrast Media outlook. It also comprehends market new product analysis, financial overview, strategies and marketing trends.

In Diagnostic Radiopharmaceuticals & Contrast Media Market Report, Following Companies Are Covered:

The Research Document Will Answer Following Questions Such as:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999529

Key Market Trends:

Cardiology Sub-segment Captured the Largest Market Share and is Expected to Retain its Dominance

The major factor driving the growth of the market is the rising prevalence of cardiovascular diseases over the world. According to the estimates of the World Health Organization (WHO), in 2016, 17.9 million people died from CVDs. SPECT, which stands for single photon emission computed tomography, is a non-invasive procedure that can accurately identify areas of abnormal myocardial perfusion. It is also used to determine the functional capacity of the heart muscle and is able to separate living tissue from an irreversibly damaged tissue. This diagnostic procedure helps physicians find out if there are blockages in the coronary (heart) arteries, as well as to determine if the patient should undergo a coronary angiogram. In SPECT, cardiac-specific radiopharmaceuticals, such as 99mTc-tetrofosmin (Myoview, GE healthcare), 99mTc-sestamibi (Cardiolite, Bristol-Myers Squibb), or Thallium-201 chloride are administered. Hence, factors, such as the rising prevalence of cardiovascular diseases and technological advancements in the field of diagnostics, are expected to drive the growth of the market over the forecast period.

North America Captured the Largest Market Share and is Expected to Retain its Dominance

North America dominated the overall diagnostic radiopharmaceuticals and contrast media market, with the United States accounting for the major contributor to the market. The US diagnostic radiopharmaceuticals and contrast media market is anticipated to continue its expansion over the forecast period. The first gadolinium-based contrast agent was approved in the United States. Four agents were approved in the United States in the past decade, and they have set a string trend in the industry to continue to find more efficient, accurate, and safe agents.

The contrast media sales are expected to increase in the United States in the coming years. Among the different imaging modalities, sales of contrast media for the ultrasound market are likely to have a considerable growth rate. Diagnostic radioisotopes are a significant component of the US economy. Increase in chronic cardiac and neurological diseases is the primary driving factor for the market growth in the United States. Hence, the North American diagnostic radiopharmaceuticals and contrast media market is expected to retain its dominance over the forecast period.

Reasons for Buying Diagnostic Radiopharmaceuticals & Contrast Media Market Report:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/13999529

Detailed TOC of Diagnostic Radiopharmaceuticals & Contrast Media Market Report 2019-2024:

1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Technology Advancements in Medical Imaging4.2.2 Increasing Demand for Image-guided Procedures and Diagnostics4.2.3 High Prevalence of Cancers and Cardiac Diseases4.3 Market Restraints4.3.1 High Costs of the Techniques- Not Easily Affordable4.3.2 Limited Health Insurance Coverage4.3.3 Short Half-life of Radiopharmaceuticals4.4 Industry Attractiveness Porters Five Forces Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION5.1 Radiopharmaceuticals5.1.1 By Type of Imaging Modality5.1.1.1 SPECT5.1.1.1.1 Tc-995.1.1.1.2 Tl-2015.1.1.1.3 Ga-675.1.1.1.4 I-1235.1.1.1.5 Other SPECTs5.1.1.2 PET5.1.1.2.1 F-185.1.1.2.2 Rb-825.1.1.2.3 Other PETs5.1.2 By Application5.1.2.1 Diagnostic Application5.1.2.1.1 SPECT Applications5.1.2.1.1.1 Cardiology5.1.2.1.1.2 Neurology5.1.2.1.1.3 Thyroid5.1.2.1.1.4 Other SPECT Applications5.1.2.1.2 PET Application5.1.2.1.2.1 Oncology5.1.2.1.2.2 Cardiology5.1.2.1.2.3 Neurology5.1.2.1.2.4 Other PET Applications5.1.2.2 Therapeutic Application5.1.2.2.1 Thyroid5.1.2.2.2 Lymphoma5.1.2.2.3 Endocrine Tumors5.1.2.2.4 Other Therapeutic Applications5.2 Contrast Media5.2.1 By Application5.2.1.1 Ionizing Radiation-based Radioimaging5.2.1.2 Non-Ionizing Radiation-based Radioimaging5.2.2 By Procedure5.2.2.1 X-ray/Computed Tomography (CT)5.2.2.1.1 Iodinated Contrast Media Ionic5.2.2.1.2 Iodinated Contrast Media Non-Ionic5.2.2.1.3 Barium-based Contrast Media5.2.2.2 Magnetic Resonance Imaging (MRI)5.2.2.2.1 Gadolinium-based Contrast Media5.2.2.2.2 Other Magnetic Resonance Imaging5.2.2.3 Ultrasound5.2.3 By Indication5.2.3.1 Cardiovascular Disease5.2.3.2 Oncology5.2.3.3 Gastrointestinal5.2.3.4 Disorders5.2.3.5 Neurological5.2.3.6 Disorders5.2.3.7 Other Indications5.3 Geography5.3.1 North America5.3.1.1 United States5.3.1.2 Canada5.3.1.3 Mexico5.3.2 Europe5.3.2.1 United Kingdom5.3.2.2 Germany5.3.2.3 France5.3.2.4 Italy5.3.2.5 Spain5.3.2.6 Rest of Europe5.3.3 Asia-Pacific5.3.3.1 China5.3.3.2 Japan5.3.3.3 India5.3.3.4 Australia5.3.3.5 South Korea5.3.3.6 Rest of Asia-Pacific5.3.4 Middle East & Africa5.3.4.1 GCC5.3.4.2 South Africa5.3.4.3 Rest of Middle East & Africa5.3.5 South America5.3.5.1 Brazil5.3.5.2 Argentina5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Bioclinica6.1.2 Bio-Optronics Inc.6.1.3 DATATRAK International Inc.6.1.4 ERT Clinical6.1.5 IBM Watson Health6.1.6 Medidata Solutions Inc.6.1.7 MedNet Solutions Inc.6.1.8 Oracle Corporation6.1.9 Parexel International Corporation6.1.10 ArisGlobal

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Laser Jet Printer Market 2025: Global Size, Key Companies, Trends, Growth and Regional Forecasts Research

Palm Oil Market 2018: Emerging Technologies, Sales Revenue, Key Players Analysis, Development Status, Opportunity Assessment and Industry Expansion Strategies 2023

Anti-Cancer Drug Market 2019 to 2025 Structure with Top down & Bottom up Approach, Technological Trends Global Forecast Report

Cufflinks Market 2019 Explosive Factors of Revenue by Key Vendors Size, Demand, Development Strategy, Future Trends and Industry Growth Research Report

Diagnostic Radiopharmaceuticals & Contrast Media Market 2019 | Remarkable Growth Factors with Industry Size & Share, New Innovations of…

Categories

Archives